Literature DB >> 34047304

Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.

Gregory J Botwin1,2, Dalin Li1,2, Jane Figueiredo2,3, Susan Cheng4, Jonathan Braun1,2,5, Dermot P B McGovern1,2,5, Gil Y Melmed1,2.   

Abstract

INTRODUCTION: Patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) on immunosuppressive and biologic therapies were largely excluded from severe acute respiratory syndrome coronavirus-2 messenger RNA vaccine trials.
METHODS: We evaluated adverse events (AE) after messenger RNA vaccination in 246 adults with IBD participating in a longitudinal vaccine registry.
RESULTS: In general, AE frequency was similar to that reported in the general population. AEs were more common among younger patients and those with previous COVID-19. AEs were less common in individuals receiving advanced therapies with biologics or small-molecule inhibitors. DISCUSSION: Those with IBD and other immune-mediated inflammatory diseases can be reassured that the AE risk is likely not increased, and may be reduced, while on advanced therapies.
Copyright © 2021 by The American College of Gastroenterology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34047304      PMCID: PMC8484025          DOI: 10.14309/ajg.0000000000001342

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   12.045


  7 in total

1.  Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.

Authors:  Brian J Boyarsky; William A Werbel; Robin K Avery; Aaron A R Tobian; Allan B Massie; Dorry L Segev; Jacqueline M Garonzik-Wang
Journal:  JAMA       Date:  2021-05-04       Impact factor: 56.272

2.  Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.

Authors:  Jonathan G Braun; Susan Cheng; Kimia Sobhani; Joseph E Ebinger; Justyna Fert-Bober; Ignat Printsev; Min Wu; Nancy Sun; John C Prostko; Edwin C Frias; James L Stewart; Jennifer E Van Eyk
Journal:  Nat Med       Date:  2021-04-01       Impact factor: 53.440

3.  Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients.

Authors:  João L Miraglia; Edson Abdala; Paulo M Hoff; André M Luiz; Danise S Oliveira; Carla G S Saad; Ieda M M Laurindo; Ana T R Viso; Angela Tayra; Lígia C Pierrotti; Luiz S Azevedo; Lúcia Maria A Campos; Nádia E Aikawa; Maria do Carmo S T Timenetsky; Expedito Luna; Maria Regina A Cardoso; José da S Guedes; Isaias Raw; Jorge Kalil; Alexander R Precioso
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

4.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

5.  COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.

Authors:  Rahul S Dalal; Emma McClure; Jenna Marcus; Rachel W Winter; Matthew J Hamilton; Jessica R Allegretti
Journal:  Clin Gastroenterol Hepatol       Date:  2021-02-04       Impact factor: 11.382

6.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

7.  First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.

Authors:  Julianne Gee; Paige Marquez; John Su; Geoffrey M Calvert; Ruiling Liu; Tanya Myers; Narayan Nair; Stacey Martin; Thomas Clark; Lauri Markowitz; Nicole Lindsey; Bicheng Zhang; Charles Licata; Amelia Jazwa; Mark Sotir; Tom Shimabukuro
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2021-02-26       Impact factor: 17.586

  7 in total
  32 in total

1.  Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study.

Authors:  Mohammad Shehab; Fatema Alrashed; Israa Abdullah; Ahmad Alfadhli; Hamad Ali; Mohamed Abu-Farha; Arshad Mohamed Channanath; Jehad Ahmed Abubaker; Fahd Al-Mulla
Journal:  Front Med (Lausanne)       Date:  2022-06-08

2.  Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies.

Authors:  Jane C Figueiredo; Fred R Hirsch; Lawrence H Kushi; Wendy N Nembhard; James M Crawford; Nicholas Mantis; Laurel Finster; Noah M Merin; Akil Merchant; Karen L Reckamp; Gil Y Melmed; Jonathan Braun; Dermot McGovern; Samir Parekh; Douglas A Corley; Namvar Zohoori; Benjamin C Amick; Ruofei Du; Peter K Gregersen; Betty Diamond; Emanuela Taioli; Carlos Sariol; Ana Espino; Daniela Weiskopf; Alba Gifoni; James Brien; William Hanege; Marc Lipsitch; David A Zidar; Ann Scheck McAlearney; Ania Wajnberg; Joshua LaBaer; E Yvonne Lewis; Raquel A Binder; Ann M Moormann; Catherine Forconi; Sarah Forrester; Jennifer Batista; John Schieffelin; Dongjoo Kim; Giulia Biancon; Jennifer VanOudenhove; Stephanie Halene; Rong Fan; Dan H Barouch; Galit Alter; Swetha Pinninti; Suresh B Boppana; Sunil K Pati; Misty Latting; Andrew H Karaba; John Roback; Rafick Sekaly; Andrew Neish; Ahnalee M Brincks; Douglas A Granger; Amy B Karger; Bharat Thyagarajan; Stefani N Thomas; Sabra L Klein; Andrea L Cox; Todd Lucas; Debra Furr-Holden; Kent Key; Nicole Jones; Jens Wrammerr; Mehul Suthar; Serre Yu Wong; Natalie M Bowman; Viviana Simon; Lynne D Richardson; Russell McBride; Florian Krammer; Meenakshi Rana; Joshua Kennedy; Karl Boehme; Craig Forrest; Steve W Granger; Christopher D Heaney; Maria Knight Lapinski; Shannon Wallet; Ralph S Baric; Luca Schifanella; Marcos Lopez; Soledad Fernández; Eben Kenah; Ashish R Panchal; William J Britt; Iñaki Sanz; Madhav Dhodapkar; Rafi Ahmed; Luther A Bartelt; Alena J Markmann; Jessica T Lin; Robert S Hagan; Matthew C Wolfgang; Jacek Skarbinski
Journal:  Open Forum Infect Dis       Date:  2022-04-27       Impact factor: 4.423

Review 3.  Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.

Authors:  Susanna Esposito; Caterina Caminiti; Rosanna Giordano; Alberto Argentiero; Greta Ramundo; Nicola Principi
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

4.  Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review.

Authors:  SeyedAhmad SeyedAlinaghi; Amirali Karimi; Zahra Pashaei; Arian Afzalian; Pegah Mirzapour; Kobra Ghorbanzadeh; Afsaneh Ghasemzadeh; Mohsen Dashti; Newsha Nazarian; Farzin Vahedi; Marcarious M Tantuoyir; Ahmadreza Shamsabadi; Omid Dadras; Esmaeil Mehraeen
Journal:  Arch Acad Emerg Med       Date:  2022-05-22

5.  Effectiveness and Safety of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease.

Authors:  Emily Spiera; Ryan C Ungaro; Asher Kornbluth
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-03

6.  Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease.

Authors:  Dalin Li; Philip Debbas; Susan Cheng; Jonathan Braun; Dermot P B McGovern; Gil Y Melmed
Journal:  medRxiv       Date:  2021-12-07

Review 7.  SARS-CoV-2 vaccination in patients with inflammatory bowel disease.

Authors:  Ralley E Prentice; Clarissa Rentsch; Aysha H Al-Ani; Eva Zhang; Douglas Johnson; John Halliday; Robert Bryant; Jacob Begun; Mark G Ward; Peter J Lewindon; Susan J Connor; Simon Ghaly; Britt Christensen
Journal:  GastroHep       Date:  2021-07-23

8.  The T-cell clonal response to SARS-CoV-2 vaccination in inflammatory bowel disease patients is augmented by anti-TNF therapy and often deficient in antibody-responders.

Authors:  Dalin Li; Alexander Xu; Emebet Mengesha; Rebecca Elyanow; Rachel M Gittelman; Heidi Chapman; John C Prostko; Edwin C Frias; James L Stewart; Valeriya Pozdnyakova; Philip Debbas; Angela Mujukian; Arash A Horizon; Noah Merin; Sandy Joung; Gregory J Botwin; Kimia Sobhani; Jane C Figueiredo; Susan Cheng; Ian M Kaplan; Dermot P B McGovern; Akil Merchant; Gil Y Melmed; Jonathan Braun
Journal:  medRxiv       Date:  2021-12-08

9.  COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study.

Authors:  Mohammad Shehab; Yasmin Zurba; Ali Al Abdulsalam; Ahmad Alfadhli; Sara Elouali
Journal:  Vaccines (Basel)       Date:  2021-12-31

10.  Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.

Authors:  Anna Viola; Marco Muscianisi; Raffaele Li Voti; Giuseppe Costantino; Angela Alibrandi; Walter Fries
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.